Musculoskeletal manifestations of endocrine disorders

Current Opinion in Rheumatology

Volumn 17, Issue 1, 2005, Pages 64-69

  Jacobs Kosmin, Dana ^a   DeHoratius, Raphael J ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Acromegaly; Diabetes mellitus; Hypercortisolism; Hyperparathyroidism; Rheumatic manifestations; Thyroid disease

Indexed keywords

PROPYLTHIOURACIL; ROSIGLITAZONE;

ACROMEGALY; ANKYLOSING HYPEROSTOSIS; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; DIABETES MELLITUS; ENDOCRINE DISEASE; HUMAN; HYPERCORTISOLISM; MUSCULOSKELETAL DISEASE; NEUROPATHIC JOINT DISEASE; OSTEOBLAST; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL; REVIEW; SHOULDER HAND SYNDROME; THYROID DISEASE; VASCULITIS;

BONE DISEASES; DIABETES COMPLICATIONS; ENDOCRINE SYSTEM DISEASES; HUMANS; INFARCTION; MUSCULAR DISEASES; THYROID DISEASES;

EID: 11344264123     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000150950.43282.df     Document Type: Review

References (44)

1. Arkkila PET, Gautier JF: Musculoskeletal disorders in diabetes mellitus: an update. Best Pract Res Clin Rheumatol 2003, 17:945-970.
2. Cagliero E: Rheumatic manifestations of diabetes mellitus. Curr Rheumatol Rep 2003, 5:189-194.
3. Ardic F, Soyupek F, Kahraman Y, Yorgancioglu R: The musculoskeletal complications seen in type II diabetics: predominance of hand involvement. Clin Rheumatol 2003, 22:229-233. A controlled study revealed the presence of hand syndromes in a significant proportion of diabetics.
4. Arkkila PE, Koskinen PJ, Kantola IM, et al.: Biochemical markers of types I and III collagen and limited joint mobility in type 1 diabetic patients. Acta Diabetol 2003, 40:151-155.
5. Sibbitt WL Jr, Eaton RP: Corticosteroid responsive tenosynovitis is a common pathway for limited joint mobility in the diabetic hand. J Rheumatol 1997, 24:931-936.
6. Eaton RP, Sibbitt WL Jr, Shah VO, et al.: A commentary on 10 years of aldose reductase inhibition for limited joint mobility in diabetes. J Diabetes Complications 1998, 12:34-38.
7. Kapur S, Brunet JA, McKendry RJ: Diabetic muscle infarction: case report and review. J Rheumatol 2004, 31:190-194. A valuable retrospective review combines data from 116 patients.
8. Habib GS, Nashashibi M, Saliba W, Haj S: Diabetic muscular infarction: emphasis on pathogenesis. Clin Rheumatol 2003, 22:450-451.
9. Sarzi-Puttini P, Atzeni F: New developments in our understanding of DISH (diffuse idiopathic skeletal hyperostosis). Curr Opin Rheumatol 2004, 16:287-292. Clinically oriented and comprehensive review focusing on the pathogenesis of DISH.
10. Lee L, Blume PA, Sumpio B: Charcot joint disease in diabetes mellitus. Ann Vasc Surg 2003, 17:571-580.
11. Ahmad T, Ohlsson C, Saaf M, et al.: Skeletal changes in type-2 diabetic Goto-Kakizaki rats. J Endocrinol 2003, 178:111-116.
12. Herbst SA, Jones KB, Saltzman CL: Pattern of diabetic neuropathic arthropathy associated with the peripheral bone mineral density. J Bone Joint Surg Br 2004, 86:378-383. Interesting study identifies subgroups of diabetics with Charcot joint disease by pattern, joint and BMD.
13. Carnevale V, Romagnoli E, D'Erasmo E: Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev 2004, 20:196-204. A critical analysis of recent data on bone involvement in diabetes considers the pathophysiological aspects, biochemical markers of bone turnover and histomorphometry, BMD and fracture risk.
14. Schwartz AV: Diabetes Mellitus: Does it affect bone? Calcif Tissue Int 2003, 73:515-519. Comprehensive review of the pathways through which diabetes affects bone and the controversies associated with current evidence.
15. Heap J, Murray MA, Miller SC, et al.: Alterations in bone characteristics associated with glycemic control in adolescents with type 1 diabetes mellitus. J Pediatr 2004, 144:56-62.
16. Liu EY, Wactawski-Wende J, Donahue RP, et al.: Does low bone mineral density start in post-teenage years in women with type 1 diabetes? Diabetes Care 2003, 26:2365-2369.
17. DeLuis Roman DA, Aller R, Perez Castrillon JL, et al.: Effects of dietary intake and life style on bone density in patients with diabetes mellitus type 2. Ann Nutr Metab 2004, 48:141-145.
18. He H, Liu R, Desta T, et al.: Diabetes causes decreased osteoclastogenesis, reduced bone formation, and enhanced apoptosis of osteoblastic cells in bacteria stimulated bone loss. Endocrinology 2004, 145:447-452.
19. Rzonca SO, Suva LJ, Gaddy D, et al.: Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004, 145:401-406. Noteworthy study of one agent in the newest class of oral antidiabetic drugs illustrates the adverse effects of rosiglitazone on bone and has important implications for diabetes management.
20. Cakir M, Samanci N, Balci N, Balci MK: Musculoskeletal manifestations in patients with thyroid disease. Clin Endocrinol (Oxf) 2003, 59:162-167.
21. D'Arbonneau F, Ansart S, Le Berre R, et al.: Thyroid dysfunction in primary Sjogren's syndrome: a long-term followup study. Arthritis Rheum 2003, 49:804-809. Patients with primary Sjogren syndrome were followed for 1-16 years in this study. Findings highlight the relevance of thyroid autoantibodies in Sjogren patients.
22. Innocencio RM, Romaldini JH, Ward LS: High prevalence of thyroid autoantibodies in systemic sclerosis and rheumatoid arthritis but not in the antiphospholipid syndrome. Clin Rheumatol 2003, 22:494.
23. Stone JH, Wegener's Granulomatosis Etanercept Trial Research Group.: Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 2003, 48:2299-2309.
24. Simsek G, Karter Y, Aydin S, Uzun H: Osteoporotic cytokines and bone metabolism on rats with induced hyperthyroidism; changes as a result of reversal to euthyroidism. Chin J Physiol 2003, 46:181-186. The role of interleukin-6 and associated cytokines in hyperthyroidism is investigated.
25. Vestergaard P, Mosekilde L: Hyperthyroidism, bone mineral, and fracture risk-a meta-analysis. Thyroid 2003, 13:585-593.
26. Acotto CG, Niepomniszcze H, Vega E, Mautalen CA: Ultrasound parameters and markers of bone turnover in hyperthyroidism: a longitudinal study. J Clin Densitom 2004, 7:201-208.
27. Lakatos P: Thyroid hormones: beneficial or deleterious for bone? Calcif Tissue Int 2003, 73:205-209. Thorough reviews discusses the effects of thyroid disorders and controversy of thyroid treatment on bone in patients with overt and subclinical thyroid disease.
28. Yamauchi K, Sata M, Machiya J, et al.: Antineutrophil cytoplasmic antibody positive alveolar haemorrhage during propylthiouracil therapy for hyperthyroidism. Respirology 2003, 8:532-535.
29. Jacobs EM, Hartkamp A, Kaasjager HA: PTU-associated cutaneous vasculitis with ANCA anti-MPO and anti-PR3 antibodies. Neth J Med 2003, 61:296-299.
30. Schneider R, Reiners C: The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature. Exp Clin Endocrinol Diabetes 2003, 111:455-470.
31. Meier C, Beat M, Guglielmetti M, et al.: Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized control trial. Osteoporos Int 2004, 15:209-216. Double-blind, placebo controlled trial demonstrated that TSH-guided levothyroxine treatment accelerates bone turnover. Larger controlled studies could confirm if this process leads to clinically important bone loss.
32. Taniegra ED: Hyperparathyroidism. Am Fam Physician 2004, 69:333-340.
33. Silverberg SJ, Bilezikian JP: Asymptomatic primary hyperparathyroidism: a medical perspective. Surg Clin North Am 2004, 84:787-801.
34. Silverberg SJ, Bilezikian JP: Incipient primary hyperparathyroidism: A Forme fruste of an old disease. J Clin Endocrinol Metab 2003, 88:5348-5352. A novel study describing patients who may represent the earliest manifestations of this hyperparathyroidism.
35. Mack LA, Pasiek JL: Asymptomatic primary hyperparathyroidism: a surgical perspective. Surg Clin North Am 2004, 84:803-816.
36. Yajima A, Ogawa Y, Takahashi HE, et al.: Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism. Am J Kidney Dis 2003, 42:729-738. Study demonstrates changes in parathyroidectomized patients potentially lead to stronger, mineralized bone.
37. Lumachi F, Ermani M, Basso SM, et al.: Short and long-term changes in bone mineral density of the lumbar spine after parathyroidectomy in patients with primary hyperparathyroidism. Calcif Tissue Int 2003, 73:44-48.
38. Liebermann SA, Bjorkengren AG, Hoffman AR: Rheumatological and skeletal changes in acromegaly. Endocrinol Metab Clin North Am 1992, 21:615-630.
39. Vestergaard P, Mosekilde L: Fracture risk is decreased in acromegaly-a potential beneficial effect of growth hormone. Osteoporos Int 2004, 15:155-159. First study of this kind to include a large sample of acromegalic patients.
40. Tran M, Elias AM: Severe myopathy and psychosis in a patient with Cushing's disease macroadenoma. Clin Neural Neurosurg 2003, 106:1-4.
41. Arnaldi G, Angeli A, Atkinson AB, et al.: Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003, 88:5593-5606. Informative consensus statement by leading endocrinologists includes discussion of and recommendations for management of osteoporosis in CS.
42. Minetto M, Reimondo G, Osella G, et al.: Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome. Osteoporos Int 2004;Mar 18. [online].
43. Karavitaki N, Ioannidis G, Giannakopoulos F, et al.: Evaluation of bone mineral density of the peripheral skeleton in pre- and postmenopausal women with newly diagnosed endogenous Cushing's syndrome. Clin Endocrinol (Oxf) 2004, 60:264-270. One of few studies to evaluate forearm BMD in endogenous CS.
44. DiSomma C, Pivonello R, Loche S, et al.: Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. Clin Endocrinol (Oxf) 2003, 58:302-308.